Network pharmacology prioritized STAT3, HSP90AA1, CASP3, CASP8, and SRC as core therapeutic targets, with molecular docking confirming stable interactions between these two metabolites and targets, highlighting their potential in managing infections, neoplasms, and metabolic disorders. The gene discussed is HSP90AA1; the disease is Other metabolic disease.